文献速递泌尿系感染

疫苗预防复发性尿路感染的系统综述

Vaccines for the prevention of recurrent urinary tract infections: a systematic review.
PubMed 文献 · BJU Int · 2018-12-19

该系统综述纳入10项随机安慰剂对照试验、共1537例复发性尿路感染成人患者,评估疫苗或免疫刺激剂降低UTI复发率的疗效。汇总分析显示疫苗组复发风险低于安慰剂组(RR 0.74,95%CI 0.67-0.81;低质量证据),但研究间异质性显著(I2=84%),常规临床推荐受限。

要点

  • 疫苗整体降低复发性UTI风险(RR 0.74,95%CI 0.67-0.81;低质量证据)。
  • Uro-Vaxom在3个月时效果最大(RR 0.67,95%CI 0.57-0.78)。
  • ExPEC4V未显示显著降低复发(RR 0.82,95%CI 0.62-1.10)。

核心结论

  • 有证据支持疫苗对复发性UTI患者有效,但研究间显著异质性使常规临床推荐目前困难。
  • 需要采用一致定义和终点的进一步随机试验研究长期疗效与安全性。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE、PubMed、Cochrane Library、WHO ICTRP及会议摘要至2018年1月。
  • 纳入10项随机安慰剂对照试验,共1537例复发性UTI成人患者,评估UTI复发率。
  • 采用随机效应模型计算风险比(RR),Cochrane工具评估偏倚风险,GRADE评估证据质量。

主要发现

  • 疫苗组UTI复发率低于安慰剂组(RR 0.74,95%CI 0.67-0.81;低质量证据)。
  • Uro-Vaxom降低复发率,3个月时RR 0.67(95%CI 0.57-0.78),6个月时RR 0.78(95%CI 0.69-0.88);低质量证据。
  • Urovac可能降低UTI复发风险(RR 0.75,95%CI 0.63-0.89;低质量证据)。
  • ExPEC4V在研究终点未显示降低UTI复发(RR 0.82,95%CI 0.62-1.10;低质量证据)。
  • 纳入研究间存在显著异质性(卡方=54.58;P<0.001,I2=84%)。

关键数值与推荐

  • 共识别599条记录,最终纳入10项研究。
  • 研究涉及3种候选疫苗:Uro-Vaxom、Urovac、ExPEC4V。

临床怎么用

  • 疫苗可能作为复发性UTI的预防选择,但证据质量低且异质性大,暂不支持常规临床推荐。
  • 临床决策需结合患者个体情况,并关注后续更高质量随机试验结果。

局限性

  • 纳入研究间存在显著异质性(I2=84%),影响结果解释与推荐。
  • 证据质量总体为低(GRADE评估)。
  • 研究终点和定义不一致,长期疗效与安全性数据缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To systematically review the evidence regarding the efficacy of vaccines or immunostimulants in reducing the recurrence rate of urinary tract infections (UTIs). MATERIALS AND METHODS: The Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), PubMed, Cochrane Library, World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal, and conference abstracts were searched up to January 2018 for English-titled citations. Randomised placebo-controlled trials evaluating UTI recurrence rates in adult patients with recurrent UTIs treated with a vaccine were selected by two independent reviewers according to the Population, Interventions, Comparators, and Outcomes (PICO) criteria. Differences in recurrence rates in study populations for individual trials were calculated and pooled, and risk ratios (RRs) using random effects models were calculated. Risk of bias was assessed using the Cochrane Collaboration's tool and heterogeneity was assessed using chi-squared and I2 testing. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence (QOE) and summarise findings. RESULTS: In all, 599 records were identified, of which 10 studies were included. A total of 1537 patients were recruited and analysed, on whom data were presented. Three candidate vaccines were studied: Uro-Vaxom® (OM Pharma, Myerlin, Switzerland), Urovac® (Solco Basel Ltd, Basel, Switzerland), and ExPEC4V (GlycoVaxyn AG, Schlieren, Switzerland). At trial endpoint, the use of vaccines appeared to reduce UTI recurrence compared to placebo (RR 0.74, 95% confidence interval [CI] 0.67-0.81; low QOE). Uro-Vaxom showed the greatest reduction in UTI recurrence rate; the maximal effect was seen at 3 months compared with 6 months after initial treatment (RR 0.67, 95% CI 0.57-0.78; and RR 0.78, 95% CI 0.69-0.88, respectively; low QOE). Urovac may also reduce risk of UTI recurrence (RR 0.75, 95% CI 0.63-0.89; low QOE). ExPEC4V does not appear to reduce UTI recurrence compared to placebo at study endpoint (RR 0.82, 95% CI 0.62-1.10; low QOE). Substantial heterogeneity was observed across the included studies (chi-squared = 54.58; P < 0.001, I2 = 84%). CONCLUSIONS: While there is evidence for the efficacy of vaccines in patients with recurrent UTIs, significant heterogeneity amongst these studies renders interpretation and recommendation for routine clinical use difficult at present. Further randomised trials using consistent definitions and endpoints are needed to study the long-term efficacy and safety of vaccines for infection prevention in patients with recurrent UTIs.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Aziminia N, Hadjipavlou M, Philippou Y, et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2018. PMID: 30378242. doi:10.1111/bju.14606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。